Trial Profile
Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Encequidar+paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Colon cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Sarcoma; Solid tumours; Uveal neoplasms
- Focus Adverse reactions; Therapeutic Use
- Sponsors Athenex
- 18 May 2023 Status changed from recruiting to discontinued.
- 09 May 2023 Planned End Date changed from 30 Jun 2023 to 30 Oct 2024.
- 09 May 2023 Planned primary completion date changed from 30 Mar 2023 to 30 Sep 2024.